Jump to content

BMS-345541

From Wikipedia, the free encyclopedia
(Redirected from C14H17N5)
BMS-345541
Identifiers
  • 4-(2′-Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17N5
Molar mass255.325 g·mol−1
3D model (JSmol)
  • n1c3c(n2c(cnc2c1NCCN)C)cc(cc3)C
  • InChI=1S/C14H17N5/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18) ☒N
  • Key:PSPFQEBFYXJZEV-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.[1]

It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.[2]

References

[edit]
  1. ^ The Journal of Biological Chemistry. 2003. 278. 1450-1456.
  2. ^ no studies found for: BMS-345541